{"schema_version":"1","generated_at":"2026-10-31T04:05:20.576Z","data_as_of":null,"url":"https://www.findmykol.com/kol/james-waisman","json_url":"https://www.findmykol.com/kol/james-waisman/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"james-waisman","name":"James Waisman","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"City Of Hope National Medical Center","institution_url":"https://www.findmykol.com/institution/city-of-hope","city":"Duarte","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1356391270","orcid":"0000-0003-2896-4146","openalex":"A5005473474"},"summary":"James Waisman is an Oncology physician affiliated with City Of Hope National Medical Center. OpenAlex indexes 211 publications with 7,125 citations (h-index 39); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":211,"cited_by_count":7125,"h_index":39,"latest_activity_year":2024,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT05533320","title":"Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in Patients With Metastatic Breast Cancer","phase":"NA","status":"WITHDRAWN","role":"Overall official","sponsor":"City of Hope Medical Center","source_url":"https://clinicaltrials.gov/study/NCT05533320","trial_url":"https://www.findmykol.com/trial/NCT05533320"},{"nct":"NCT02648477","title":"Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"City of Hope Medical Center","source_url":"https://clinicaltrials.gov/study/NCT02648477","trial_url":"https://www.findmykol.com/trial/NCT02648477"}],"source":"trials"},"payments":{"company_count":9,"program_years":{"first":2021,"last":null},"rows_total":12,"shown":3,"withheld":9,"rows":[{"payer":"TAIHO ONCOLOGY, INC.","program_year":2023,"amount_usd":4259,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1356391270"},{"payer":"NOVARTIS PHARMACEUTICALS CORPORATION","program_year":2023,"amount_usd":166.66,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1356391270"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2023,"amount_usd":36.13,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1356391270"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1356391270","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer","year":2024,"journal":"Cell Reports Medicine","source_url":"https://doi.org/10.1016/j.xcrm.2024.101420","status":"verified"},{"title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","year":2023,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2023.08.003","status":"verified"},{"title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","year":2022,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2022.09.159","status":"verified"},{"title":"Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer","year":2022,"journal":"JCI Insight","source_url":"https://doi.org/10.1172/jci.insight.153963","status":"verified"},{"title":"Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer","year":2021,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1136/jitc-2020-002084","status":"verified"}],"source":"works"},"contact":{"address_1":"1500 DUARTE RD","city":"Duarte","state":"CA","zip":"910103012","phone":"626-359-8111","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1356391270","source":"identity"},"similar":[{"name":"Erminia Massarelli","slug":"erminia-massarelli","institution":"City Of Hope National Medical Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/erminia-massarelli","json_url":"https://www.findmykol.com/kol/erminia-massarelli/profile.json"},{"name":"Swetha Thiruvengadam","slug":"swetha-thiruvengadam","institution":"City Of Hope National Medical Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/swetha-thiruvengadam","json_url":"https://www.findmykol.com/kol/swetha-thiruvengadam/profile.json"},{"name":"Yuman Fong","slug":"yuman-fong","institution":"City Of Hope National Medical Center","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/yuman-fong","json_url":"https://www.findmykol.com/kol/yuman-fong/profile.json"},{"name":"Ravi Salgia","slug":"ravi-salgia","institution":"City Of Hope National Medical Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/ravi-salgia","json_url":"https://www.findmykol.com/kol/ravi-salgia/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":9,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2020-11-17","provider_certified":"2020-11-17","collected_at":"2026-10-31T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}